[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349670-105":59,"doc-detail-349670-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","outcomes-of-adult-patients-with-li-fraumeni-syndrome-and-myeloid-neoplasms","Outcomes of adult patients with Li-Fraumeni syndrome and myeloid neoplasms","","Li-Fraumeni syndrome (LFS) is an inherited cancer predisposition in which therapy-related myeloid neoplasms (MNs) are described but not considered LFS defining tumors; treatment strategies and clinical outcomes require further evaluation. A retrospective analysis assessed patients with LFS who developed an MN, characterizing diagnosis timing, disease types, response to frontline and subsequent therapies, and survival. Results included response rates and overall survival estimates with limited durability and a subset receiving hematopoietic stem cell transplantation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/outcomes-of-adult-patients-with-li-fraumeni-syndrome-and-myeloid-neoplasms/349670/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/outcomes-of-adult-patients-with-li-fraumeni-syndrome-and-myeloid-neoplasms/349670.png","ImageObject",300,407,{"name":92,"@type":93},"moss~","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of this study on Li-Fraumeni syndrome patients who developed myeloid neoplasms?","Question",{"text":112,"@type":113},"To evaluate treatment approaches and clinical outcomes in LFS patients who developed a myeloid neoplasm, since evidence is limited and guidance is unclear.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What types of myeloid neoplasms were observed in the cohort?",{"text":117,"@type":113},"Among patients with MN, most had myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), with a smaller fraction having T-myeloid mixed phenotype acute leukemia (MPAL).",{"name":119,"@type":110,"acceptedAnswer":120},"How did survival outcomes compare after treatment, and what does the study conclude?",{"text":121,"@type":113},"Overall survival was limited, with poor long-term outcomes despite short-lived response patterns; the study concludes that additional research is needed to prevent MN and improve treatment in LFS.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349670,1790359578,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","DOI: 10. 1002/cncr.70613  \nORIGINAL ARTICLE  \nOutcomes of adult patients with Li-Fraumeni syndrome and myeloid neoplasms  \nJayastu Senapati MD, DM1,2  | Hiam M. Abdel-Salam MS2 |  \nVladislav D. Jdanov MD3 | Sanam Loghavi MD4 | Ashley Woodson MS2 | Jessica Corredor MS2 | Gautam Borthakur MD 1 | Naval G. Daver MD 1  | Tapan M. Kadia MD 1  | Koichi Takahashi MD, PHD1  | Yesid Alvarado MD 1 | Naveen Pemmaraju MD 1  | Uday R. Popat MD5  | Elizabeth J. Shpall MD5 | Farhad Ravandi MD 1 | Florencia McAllister MD2,6  | Najat C. Daw MD2,7 | Guillermo Garcia-Manero MD 1  | Banu K. Arun MD2,8  |  \nCourtney D. DiNardo MD, MSCE 1,2   \n1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA  \n2Clincial Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA  \n3Department of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA  \n4Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA  \n5Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 6Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 7Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA  \n8Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA  \nCorrespondence  \nCourtney D. DiNardo, Department of Leukemia, 1515 Holcombe Blvd., Unit 428, The University of Texas MD, Houston, TX 77030, USA.  \nEmail: [cdinardo@mdanderson.org](cdinardo@mdanderson.org)  \nAbstract  \nBackground: Li-Fraumeni syndrome (LFS) is an inherited cancer predisposition syndrome. Hematologic malignancies are not considered LFS defining tumors, however, both acute lymphoblastic leukemia and therapy-related myeloid neoplasms (MNs) in LFS are described. Treatment approaches and outcomes of MN in LFS need further evaluation.  \nMethods: The authors performed a retrospective analysis to understand treatment approaches and outcomes in patients with LFS who developed an MN.  \nResults: Among 190 patients with LFS between February 2001 and February 2026 with a history of at least one neoplasm, 14 (7%) had an MN. Median age at MN diagnosis was 43 years (range, 25–73) and 11 (79%) patients were female. Overall, eight (57%) patients had myelodysplastic syndrome (MDS), five (36%) had acute myeloid leukemia (AML), and one (7%) had T-myeloid mixed phenotype acute leukemia (MPAL). With frontline therapy, six (75%) patients with MDS and one (17%) patient with AML achieved an overall response. Considering all lines of therapy received, cumulatively six (75%) patients with MDS and five (83%) patients with AML/MPAL achieved an overall response. At a median follow-up of 28.8 months, the median overall survival (OS) was 18.2 months, and 1-year and 2-year OS rates were 77% and 17%, respectively. Five patients (two MDS, two AML, and one MPAL) underwent hematopoietic stem cell transplantation during their MN therapy with a median OS of 19.3 months.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2026 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.  \nCancer. 2026;e70613.  \n[https://doi.org/10.1002/cncr.70613](https://doi.org/10.1002/cncr.70613)  \nwi[leyonlinelibrary.com/journal/cncr](leyonlinelibrary.com/journal/cncr)  \n1 of 9  \nFunding information  \nThe University of Texas MD Anderson Cancer Center, Grant/Award Number: CA016672; The University of Texas MD Anderson SPORE, Grant/Award Number: C1100632  \nConclusion: Although short-lived responses to leukemia-directed ther","cbCailmjgU4OfYYS","https://ap.wps.com/l/cbCailmjgU4OfYYS","pdf",634640,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What was the purpose of this study on Li-Fraumeni syndrome patients who developed myeloid neoplasms?\",\"answer\":\"To evaluate treatment approaches and clinical outcomes in LFS patients who developed a myeloid neoplasm, since evidence is limited and guidance is unclear.\"},{\"question\":\"What types of myeloid neoplasms were observed in the cohort?\",\"answer\":\"Among patients with MN, most had myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), with a smaller fraction having T-myeloid mixed phenotype acute leukemia (MPAL).\"},{\"question\":\"How did survival outcomes compare after treatment, and what does the study conclude?\",\"answer\":\"Overall survival was limited, with poor long-term outcomes despite short-lived response patterns; the study concludes that additional research is needed to prevent MN and improve treatment in LFS.\"}]","Outcomes of adult patients with Li-Fraumeni syndrome and myeloid neoplasms | PDF",1790084908,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e6ab3fed3e21e73e68038e8993366ab.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad1bae132e07444ea330d1c8cf0eef31.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7af88ea18c946015dc55b06bed304985.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ce8550059778419c6a6dfd1bca6b692.webp",980,1287]